EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

FGFR2 fusion/rearrangement is associated with favorable prognosis and immunoactivation in patients with intrahepatic cholangiocarcinoma

Shaoqing Liu, Jialei Weng, Manqing Cao, Qiang Zhou, Min Xu, Wenxin Xu, Zhiqiu Hu, Minghao Xu, Qiongzhu Dong, Xia Sheng, Chenhao Zhou, Ning Ren iD

The Oncologist · 06.12.2024 · 29 (12) · e1734-e1747

DOI: 10.1093/oncolo/oyae170 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Oncologist, online erschienen am 10.07.2024. Verfasst von Shaoqing Liu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and C…. Hauptthemen laut MEDLINE: Cholangiocarcinoma, Receptor, Fibroblast Growth Factor, Type 2, Bile Duct Neoplasms. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Sino-German Mobility Program, Special Foundation for Science and Technology Basic Research Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Increasing evidence highlights that fibroblast growth factor receptor 2 (FGFR2) fusion/rearrangement shows important therapeutic value for patients with intrahepatic cholangiocarcinoma (ICC). This study aims to explore the association of FGFR2 status with the prognosis and immune cell infiltration profiles of patients with ICC. A total of 226 ICC tissue samples from patients who received surgery at the Department of Liver Surgery at Zhongshan Hospital, Fudan University, were collected retrospectively and assigned to a primary cohort (n = 152) and validation cohort (n = 74) group. Fluorescence in situ hybridization was performed to determine FGFR2 status. Multiplex immunofluorescence (mIF) staining and immunohistochemistry were performed to identify immune cells. Thirty-two (14.2%) ICC tissues presented with FGFR2 fusion/rearrangement. FGFR2 fusion/rearrangement was associated with low levels of carcinoembryonic antigen (CEA, P = .026) and gamma glutamyl transferase (γ-GGT, P = .003), low TNM (P = .012), CNLC (P = .008) staging as well as low tumor cell differentiation (P = .016). Multivariate COX regression analyses revealed that FGFR2 fusion/rearrangement was an independent protective factor for both overall survival (OS) and relapse-free survival in patients with ICC. Furthermore, correlation analysis revealed that an FGFR2 fusion/rearrangement was associated with low levels of Tregs and N2 neutrophils and high levels of N1 neutrophils infiltrating into tumors but not with CD8+ T-cell or macrophage tumor infiltration. FGFR2 fusion/rearrangement may exert a profound impact on the prognosis of ICC patients and reprogram the tumor microenvironment to be an immune-activated state. FGFR2 status may be used for ICC prognostic stratification and as an immunotherapeutic target in patients with ICC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CholangiocarcinomaReceptor, Fibroblast Growth Factor, Type 2Bile Duct NeoplasmsHumansMaleFemalePrognosisMiddle AgedAgedRetrospective StudiesAdult

Stichwörter der Autor:innen

FGFR2fusion/rearrangementimmune contextureintrahepatic cholangiocarcinomaprognosis

Substanzen

Receptor, Fibroblast Growth Factor, Type 2FGFR2 protein, human

Autor:innen und Institutionen

  • Department of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Shanghai, 200032, People's Repu…
  • Key Laboratory of Whole-Period Monitoring and Precise Intervention of Digestive Cancer of Shanghai Municipal Health Commission, Shanghai, 201199, People's Republic of China.
  • Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, 300060, Pe…
  • Institute of Fudan-Minhang Academic Health System, Minhang Hospital, Fudan University, Shanghai, 201199, People's Republic of China.
  • Department of Pathology, Minhang Hospital, Fudan University, Shanghai, 201199, People's Republic of China.

ORCID-Profile: Ning Ren

Förderung

  • National Natural Science Foundation of China
  • Sino-German Mobility Program
  • Special Foundation for Science and Technology Basic Research Program
  • Shanghai Sailing Program
  • China Postdoctoral Science Foundation
  • Shanghai Shen Kang Hospital Development Center New Frontier Technology Joint Project
  • Natural Science Research Project of Minhang District

Zitieren

APA

Liu, S., Weng, J., Cao, M., Zhou, Q., Xu, M., Xu, W., Hu, Z., Xu, M., Dong, Q., Sheng, X., Zhou, C., & Ren, N. (2024). FGFR2 fusion/rearrangement is associated with favorable prognosis and immunoactivation in patients with intrahepatic cholangiocarcinoma. The Oncologist, 29(12), e1734-e1747. https://doi.org/10.1093/oncolo/oyae170

Vancouver

Liu S, Weng J, Cao M, Zhou Q, Xu M, Xu W, et al. FGFR2 fusion/rearrangement is associated with favorable prognosis and immunoactivation in patients with intrahepatic cholangiocarcinoma. The Oncologist. 2024;29(12):e1734-e1747. doi:10.1093/oncolo/oyae170

BibTeX
@article{Liu2024,
  author = {Liu, Shaoqing and Weng, Jialei and Cao, Manqing and Zhou, Qiang and Xu, Min and Xu, Wenxin and Hu, Zhiqiu and Xu, Minghao and Dong, Qiongzhu and Sheng, Xia and Zhou, Chenhao and Ren, Ning},
  title = {FGFR2 fusion/rearrangement is associated with favorable prognosis and immunoactivation in patients with intrahepatic cholangiocarcinoma},
  journal = {The Oncologist},
  year = {2024},
  volume = {29},
  number = {12},
  pages = {e1734--e1747},
  doi = {10.1093/oncolo/oyae170}
}
Kostenlos starten →